We study the proteins expressed by immune cells – those proteins circulating in human plasma – to discover novel therapeutics. Our motivation is to reverse disease pathology.
Our work is highly interdisciplinary and collaborative, and intersects the domains of epigenetics and gene expression modulation, proteomic discovery, and synthetic protein mimicry for biological applications.
Our process starts with nature-inspired molecular design, chemical synthesis, and finally, rigorous in vitro and in vivo testing for the intended medical use.
2008 – Dr. Barron invents antimicrobial “peptoid” structures.
- “Selective Poly-N-Substituted Glycine Antibiotics” patent is submitted.
- World-wide patent granted in 2013. Additional key MaxWell patents issued to Annelise Barron, PhD, funded by US Department of Energy, National Institutes of Health, NorthWestern University and Stanford University.
2015 – MaxWell is founded and funded by Joshua McClure.
- MaxWell is a Public Benefit Company with a public benefit statement “to create health for the world, safely and affordably.”
- MaxWell begins development of deep learning software to deeply analyze biophysics of human plasma later called “MaxWell Brain” now powering isitAlzheimers.org and MaxWells human plasma research.
2016 – Dr. Barron and MaxWell team up.
- MaxWell begins sponsorship of Stanford University’s Barron Lab, and Dr Annelise Barron, PhD, joins the board of directors in agreement to assign Dr Barron’s important “Selective Poly-N-Substituted Glycine Antibiotics” patent and others to company.
- MaxWell launches world’s first young donor plasma registry.
2017 – Heterochronic Optimized Plasma Exchange (HOPE)
- Dr. David Haase, a former Mayo Clinic clinician joins MaxWell, as board member and Chief Medical Officer
- Dr. Haase and MaxWell begin planning investigation of Heterochronic Optimized Plasma Exchange
- MaxWell collaborates with Stanford University to study the proteomics of human plasma.
- MaxWell secures exclusive rights to patented key innate immune antimicrobial peptide bio-mimics.
2018 – Gene expression modulation inventions
- MaxWell’s CEO, Joshua McClure, co-invents gene expression modulation therapy with Dr Barron alongside Stanford University’s bioengineering and neurology research teams – a new polytherapy designed to treat Alzheimer’s Disease and other degenerative diseases of aging via gene expression modulation.
- MaxWell secures exclusive rights to a University of California, Berkeley patent associated with heterochronic plasma exchange.
- McClure, Haase, and Barron coinvent “Gene Expression Modulation in a Human Bioreactor” in order to be able to modulate the protein content of donor plasma used in therapeutic plasma exchange, plasma infusions, surgeries and transplants.